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Abstract
Introduction: Extracellular matrix (ECM) turnover is controlled by the synthetic rate of matrix proteins, including type I 
collagen, and their enzymatic degradation by matrix metalloproteinases (MMPs). Fibrosis is characterized by an 
unbalanced accumulation of ECM leading to organ dysfunction as observed in systemic sclerosis. We previously 
reported that proteasome inhibition (PI) in vitro decreases type I collagen and enhances MMP-1 production by human 
fibroblasts, thus favoring an antifibrotic fibroblast phenotype. These effects were dominant over the pro-fibrotic 
phenotype induced by transforming growth factor (TGF)-β. Here we investigate the molecular events responsible for 
the anti-fibrotic phenotype induced in fibroblasts by the proteasome inhibitor bortezomib.
Methods: The steady-state mRNA levels of COL1A1, COL1A2, TIMP-1, MMP-1, and MMP-2 were assessed by quantitative 
PCR in human dermal fibroblasts cultured in the presence of TGF-β, bortezomib, or both. Transient fibroblast 
transfection was performed with wild-type and mutated COL1A1 and MMP-1 promoters. Chromatin 
immunoprecipitation, electrophoretic mobility shift assay (EMSA), and DNA pull-down assays were used to assess the 
binding of c-Jun, SP1, AP2, and Smad2 transcription factors. Immunoblotting and immunofluorescent microscopy 
were performed for identifying phosphorylated transcription factors and their cellular localization.
Results: Bortezomib decreased the steady-state mRNA levels of COL1A1 and COL1A2, and abrogated SP1 binding to 
the promoter of COL1A2 in both untreated and TGF-β-activated fibroblasts. Reduced COL1A2 expression was not due 
to altered TGF-β-induced Smad2 phosphorylation, nuclear translocation, or binding to the COL1A2 promoter. In 
contrast to collagen, bortezomib specifically increased the steady-state mRNA levels of MMP-1 and enhanced the 
binding of c-Jun to the promoter of MMP-1. Furthermore, disruption of the proximal AP-1-binding site in the promoter 
of MMP-1 severely impaired MMP-1 transcription in response to bortezomib.
Conclusions: By altering the binding of at least two transcription factors, c-Jun and SP1, proteasome inhibition results 
in increased production of MMP-1 and decreased synthesis of type I collagen in human dermal fibroblasts. Thus, the 
antifibrotic phenotype observed in fibroblasts submitted to proteasome inhibition results from profound modifications 
in the binding of key transcription factors. This provides a novel rationale for assessing the potential of drugs targeting 
the proteasome for their anti-fibrotic properties.
Introduction
The extracellular matrix (ECM) provides a controlled
environment for cellular differentiation and tissue devel-
opment, thereby participating in the maintenance of
organ morphology and function. ECM integrity results
from a continuous and tightly regulated deposition and
degradation of its components. Type I collagen is among
the most abundant ECM proteins and its excessive der-
mal deposition is one of the key features of systemic scle-
rosis (SSc) (scleroderma), a prototypic fibrotic condition
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[1-3]. Type I collagen forms a characteristic triple-helix
structure composed of two alpha1 subunits and one
alpha2 subunit, encoded by the collagen 1A1 (COL1A1)
and COL1A2 genes, of which the coordinated transcrip-
tion rates ensure a 2:1 ratio [4].
Among various soluble molecules inducing the produc-
tion of type I collagen, the most extensively studied is
transforming growth factor-beta (TGF-β) [5,6]. TGF-β-
responsive elements have been mapped in the -378/-183
region of the mouse and human COL1A2 promoter [7,8].
TGF-β-mediated increase in the production of type I col-
lagen results from increased binding of transcription fac-
tors to three GC-rich SP1 sites (in the -303/-271 region)
and one activation protein-1 (AP-1) site (-265/-241)
within the COL1A2 promoter [9]. SP1 binding is essential
since blocking SP1 recruitment by point mutations in the
DNA consensus sequence leads to inhibition of type I col-
lagen synthesis, and overexpression of SP1 stimulates
both basal and TGF-β-mediated COL1A2 transcription
[8]. Furthermore, Smad2/3 signaling molecules induced
by TGF-β [10] bind to the SP1 consensus sequence in the
COL1A2 promoter region. Smad2/3 interacts also with
the transcriptional co-activators p300/CREB-binding
protein (CBP), which enhance both basal and TGF-β-
induced COL1A2 promoter activity [11].
Matrix metalloproteinases (MMPs) play a major role in
ECM degradation. They are regulated at the transcrip-
tional level and undergo post-transcriptional maturation
and their catalytic activity is inhibited by tissue inhibitors
of MMP (TIMPs) [12,13]. MMP-1 or interstitial collage-
nase unwinds native type I collagen and initiate its degra-
dation, whereas MMP-2 and MMP-9 are two gelatinases,
which efficiently digest degraded collagen. Interestingly,
these MMPs are not co-ordinately regulated. Tumor
necrosis factor-alpha (TNF-α) enhances MMP-1 [14] and
MMP-9 [15] expression, whereas TGF-β enhances MMP-
2 [16] and MMP-9 [17] synthesis but decreases MMP-1
production [18].
The proteasome is a barrel-shaped, multi-catalytic pro-
tease complex present in the cytosol and in the nuclei and
triggers degradation of multi-ubiquitinated proteins [19].
It maintains cell homeostasis by promoting clearance of
damaged or improperly folded proteins and degrades key
components involved in the cell cycle and cell signaling
[20]. We recently reported that proteasome inhibition
(PI) profoundly modifies the phenotype of human dermal
fibroblasts by reducing type I collagen synthesis and
increasing MMP-1 production [21]. This effect was dom-
inant on the pro-fibrotic activity of TGF-β and observed
i n  n o r m a l  a s  w e l l  a s  S S c  f i b r o b l a s t s .  F u r t h e r m o r e ,  P I
induced the phosphorylation, accumulation, and nuclear
translocation of c-Jun. These in vitro characteristics are
consistent with the anti-fibrotic activity exerted by PI in
many, but not all, in vivo models of fibrosis [22-27].
In the present study, we aimed at dissecting the molec-
ular mechanisms involved in the anti-fibrotic activity of
PI on human dermal fibroblasts. We inhibited the protea-
some with bortezomib, a highly specific and potent PI
used in humans as a therapeutic agent for multiple
myeloma [28-30]. We provide evidence that the anti-
fibrotic property of PI results from both the induction of
MMP-1  expression via proximal AP-1 sites and the
repression of COL1A2 transcription via SP1 sites.
Materials and methods
Cell culture
A primary human fibroblast cell line was established
from skin punch biopsies of a healthy donor, as described
previously [21]. Permission to perform this investigation
was granted by the ethics committee of our institution.
Informed consent was obtained in accordance with the
Declaration of Helsinki. Fibroblasts were maintained in
Dulbecco's modified Eagle's medium (Invitrogen Corpo-
ration, Carlsbad, CA, USA), supplemented with 10% fetal
calf serum (FCS) (Sigma-Aldrich, St. Louis, MO, USA), 2
mM glutamine (Invitrogen Corporation), non-essential
amino acids (Invitrogen Corporation), 50 U/mL penicil-
lin, and 50 μg/mL streptomycin (Invitrogen Corporation)
and grown in 5% CO2 at 37°C. Fibroblasts used at pas-
sages 5 to 14 were grown up to 80% confluence, starved
overnight in medium containing 1% FCS, and then cul-
tured in the presence of TGF-β (5 ng/mL), bortezomib (1
μM), or TNF-α (10 ng/mL) for the desired periods of
time.
Reagents and antibodies
Bortezomib (PS-341, Velcade) was from Millennium
Pharmaceuticals (Cambridge, MA, USA). TGF-β and
TNF-α were from R&D Systems, Inc. (Minneapolis, MN,
USA). Immunolabeling and immunoprecipitation were
performed using anti-type I collagen (SouthernBiotech,
Birmingham, AL, USA), anti-MMP-1 (Chemicon Inter-
national Inc., Temecula, CA, USA), anti-phospho-c-Jun,
anti-phospho-Smad2, and anti-c-Jun (Cell Signaling
Technology, Inc., Beverly, MA, USA), anti-AP2, anti-SP1,
anti-p300, anti-Ets1, and anti-TFIIEα (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA, USA), anti-Smad2/3
(Upstate, now part of Millipore Corporation, Billerica,
MA, USA), anti-β-tubulin (Sigma-Aldrich) primary anti-
bodies, and anti-goat (The Binding Site, Birmingham,
UK) or anti-rabbit or anti-mouse (DakoCytomation, Baar,
Switzerland) IgG antibodies coupled to horseradish per-
oxidase. For DNA pull-down assays, streptavidin agarose
beads were from Pierce Biotechnology (Rockford, IL,
USA).Goffin et al. Arthritis Research & Therapy 2010, 12:R73
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Quantitative reverse transcription-polymerase chain 
reaction
Total RNA was extracted with TRIzol reagent (Invitrogen
Corporation), and 1 μg was reverse-transcribed using
random primers and Superscript II (Invitrogen Corpora-
tion). Real-time polymerase chain reaction (PCR) was
performed with an ABI PRISM SDS 7900 instrument
(Applied Biosystems, Foster City, CA, USA) using Taq-
Man probes (Applied Biosystems) and with an ABI
PRISM SDS 7700 instrument using an SYBR-Green based
kit for quantitative PCR (Eurogentec, Liege, Belgium). For
each sample, gene expression was normalized using
human elongation factor 1 mRNA (HsEEF1A1). Primers
used for PCR are listed in Table 1.
Immunoblotting and enzyme-linked immunosorbent assay
Type I collagen, MMP-1, MMP-2, and TIMP-1 proteins
were quantified in the supernatants of fibroblasts submit-
ted to various culture conditions for 48 hours. Type I col-
lagen and MMP-1 were quantified by immunoblotting in
culture supernatants concentrated to one tenth of their
original volume using Vivaspin 6-mL concentrators (Sar-
torius AG, Goettingen, Germany). Total protein (20 μg)
was resolved by SDS-PAGE, transferred onto nitrocellu-
lose membranes (Hybond; Amersham Biosciences, now
part of GE Healthcare, Little Chalfont, UK), and immu-
noblotted with specific antibodies [21]. Signals were
revealed according to enhanced chemiluninescence
(ECL) protocols (GE Healthcare) and quantified by phos-
phor imaging. TIMP-1 and MMP-2 were quantified by
enzyme-linked immunosorbent assay in accordance with
the instructions of the manufacturer (R&D Systems, Inc.).
Transient cell transfection and reporter gene assays
Plasmids carrying the Renilla luciferase gene under con-
trol of the constitutive Herpes simplex virus thymidine
kinase (TK) promoter (pGL4.74) and plasmids carrying
the firefly luciferase gene under control of the constitu-
tive SV40 promoter (pLG4.13) were purchased from Pro-
mega Corporation (Madison, WI, USA). The pLG2-
derived plasmids, containing the wild-type (TGACTCA)
or variant (TTACGTCA) AP-1 site situated at -72 of the
MMP-1 promoter, were kindly provided by Franck Ver-
recchia (Hôpital Saint-Louis, Paris, France) [31]. The
pLG2-derived plasmids containing the wild-type (-311/
+114) or deleted (-112/+114) COL1A1  promoter were
kindly provided by Philippe Galera (CHU, Caen, France)
[32]. A promoter-free plasmid encoding firefly luciferase
(pLG4.10) was used as a negative control. The day before
transfection, fibroblasts were seeded in six-well plates to
reach 80% confluence. Various combinations of plasmid
DNA (1 μg total) and 3 μL of transfection reagent (Trans-
fast from Promega Corporation) were added to 1 mL of
medium containing 1% FCS and mixed vigorously. The
Table 1: Oligonucleotide sequences
Name Sequence
Electrophoretic mobility 
shift assay
MMP-1 AP-1 S CTAGTGATGAGTCAGCCGGATC
MMP-1 AP-1 AS GATCCGGCTGACTCATCACTAG
Chromatin 
immunoprecipitation
MMP-1 AP-1 fw CCTCTTGCTGCTCCAATATC
MMP-1 AP-1 rv TCTGCTAGGAGTCACCATTTC
MMP-2 AP2 fw GTGGAGGAGGGCGAGTAGGG
MMP-2 AP2 rv CTGGGAGGGAGCTGGCAGAG
MMP-9 AP-1 fw GAGAGGAGGAGGTGGTGTAAG
MMP-9 AP-1 rv TTAAGGAGGCGCTCCTGTG
COL1A1 -200/+100 fw CAGAGCTGCGAAGAGGGGA
COL1A1 -200/+100 rv AGACTCTTTGTGGCTGGGGAG
COL1A2 fw2 GCGGAGGTATGCAGACAACG
COL1A2 rv1 GGGCTGGCTTCTTAAATTG
MMP-1 ORF fw TAAGTACTGGGCTGTTCAGG
MMP-1 ORF rv GAGCAGCATCGATATGCTTC
COL1A2 ORF fw GCCCTCAAGGTTTCCAAG
COL1A2 ORF rv GGGAGACCCATCATTTCAC
Reverse transcription-
polymerase chain reaction
COL1A1 Hs00164004_m1
COL1A2 Hs00164099_m1
TIMP-1 Hs00171558_m1
MMP-1 Hs00233958_m1
MMP-2 Hs00234422_m1
HsEEF1A1 CACCTGAGCAGTGAAGCCAGCTGCTT
DNA pull-down assay
Biotin-MMP-1-S GATCGAGAGGATGTTATAAAGCATG
AGTCAG
Biotin-MMP-1-AS CTGACTCATGCTTTATAACATCCTCT
CGATC
Biotin-COL1A2-S GAAAGGGCGGGGGAGGGCGGGAG
GATGCGGAGGGCGGAG
Biotin-COL1A2-AS CTCCGCCCTCCGCATCCTCCCGCCC
TCCCCCGCCCTTTC
Bold case indicates proximal activation protein-1 (AP-1) site. 
Underlining indicates transcription binding sites (Ets and AP-1 for 
matrix metalloproteinase-1 [MMP-1] and SP1 for collagen 1A2 
[COL1A2]).Goffin et al. Arthritis Research & Therapy 2010, 12:R73
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transfection mix contained Renilla luciferase and firefly
luciferase plasmids at a ratio of 1 to 10. After 10 minutes
at room temperature, the cultures were placed for 1 hour
at 37°C, 2 mL of medium containing 10% FCS was added
to each well, and the cells were incubated for 48 hours at
37°C. Cell lysis was performed as recommended by the
manufacturer (Promega Corporation), and luciferase
activities were measured with a Luminometer (Luminos-
kan Ascent®; Thermo LabSystems, now part of Thermo
Electron Corporation, Waltham, MA, USA) using the
Dual-Luciferase Reporter Assay from Promega Corpora-
tion. Firefly luciferase activity was normalized to that of
Renilla luciferase. The corrected activities reflect the
induction of the tested promoters.
Chromatin immunoprecipitation
Chromatin was prepared and immunoprecipitated as
previously described [33]. Immunoprecipitated DNA
derived from 1 μg of input chromatin DNA and a series of
standards containing 0.01 to 10 ng of total input chroma-
tin DNA were analyzed by real-time PCR using primers
listed in Table 1. The amount of immunoprecipitated
DNA was calculated from a standard curve generated
with the input chromatin. Real-time PCR amplifications
were repeated in triplicate.
Nuclear extracts
Fibroblasts were washed twice with ice-cold phosphate-
buffered saline (PBS) and collected with a rubber police-
man in 1 mL of PBS containing 1 mM ethylenedi-
aminetetraacetic acid (EDTA). Cells were lysed for 15
minutes on ice in hypotonic buffer (10 mM Hepes pH 7.9;
10 mM KCl; 0.1 mM EDTA; 0.1 mM EGTA; 1 mM dithio-
threitol [DTT]; 0.15 vol/vol complete protease inhibitor
mix from Roche [Basel, Switzerland]; 0.2 mM phenylm-
ethylsulfonyl fluoride [PMSF]; 100 nM okadaic acid; and
1 mM orthovanadate). The cell lysate was centrifuged at
13,000 rpm for 30 seconds, the supernatants were dis-
carded, and the nuclei were suspended in extraction buf-
fer (20 mM Hepes pH 7.9; 0.4 M NaCl; 1 mM EDTA; 1
mM EGTA; 1 mM DTT; 0.15 vol/vol complete protease
inhibitor mix from Roche; and 0.2 mM PMSF). Samples
were shaken vigorously for 15 minutes at 4°C and centri-
fuged for 5 minutes at 13,000 rpm, and the supernatants
were collected.
Electrophoretic mobility shift assay
Complementary oligonucleotides (listed in Table 1) were
mixed in a 1:1 molar ratio at 100 pmole/μL, heated for 5
minutes at 95°C, and slowly cooled down to room tem-
perature. Hybridized DNA probes were radiolabeled with
γ-32P-ATP in the presence of T4 polynucleotide kinase
(Invitrogen Corporation) and purified by chromatogra-
phy using a Sephadex G-25 spin column (Roche). An ali-
quot of labeled probe (2 × 104 cpm) was incubated with 5
μg of nuclear extract in binding buffer (nuclear extraction
buffer containing 130 ng/μL Poly dIdC, 0.7 mg/mL
bovine serum albumin, and 15% glycerol) for 30 minutes
at room temperature. Alternatively, the nuclear extract
was pre-incubated for 30 minutes at room temperature
prior to addition of the probe, with 1 μg of specific anti-
bodies for supershift assays or with a 100-fold excess of
cold probe for competition experiments. Protein-DNA
complexes were resolved on non-denaturing 4% poly-
acrylamide gels, and radioactive bands were detected
with x-ray films (Kodak BioMax MR film from Sigma-
Aldrich).
DNA pull-down assays
Complementary biotinylated oligonucleotides (listed in
Table 1) were hybridized as described in the EMSA pro-
tocol. Annealed biotinylated DNA (1 μg) was incubated
with 300 μg of nuclear extract in binding buffer (supple-
mented with 0.2 mg/mL sheared salmon DNA) for 30
minutes at room temperature, and streptavidin-agarose
beads were then added in binding buffer (supplemented
with 0.2 mg/mL sheared salmon DNA and 150 mM
NaCl) for 3 hours at 4°C. Following three washes in
blocking buffer, beads were boiled in Laemmli buffer and
eluted proteins were resolved and immunoblotted as
described above. Normalization to the total nuclear pro-
tein content was performed by Western immunoblotting
of the input fractions with anti-TFIIEα antibody.
Immunofluorescence
Fibroblasts were seeded on coverslips in six-well plates (5
× 104 cells per well). Cells were washed in PBS, fixed in 4%
paraformaldehyde for 20 minutes at room temperature,
incubated successively in 1 mM NH4Cl and 4% Tween,
labeled with primary antibody for 1 hour, and then incu-
bated with alexa488-coupled anti-rabbit IgG antibody
(Invitrogen Corporation) for 45 minutes at room temper-
ature. Subcellular localization was observed with a fluo-
rescence microscope (Axiovert 200, Carl Zeiss,
Gottingen, Germany), and photographs were taken at a
magnification of × 40.
Statistical analysis
The Student t test was used for statistical analysis. A P
value of less than 0.05 was considered significant. To
assess the normal distribution of our data, we assessed
their skewness and kurtosis, which provided values con-
sistent with normal distribution using the GraphPad
Prism version 4.00 (GraphPad Software, Inc., San Diego,
CA, USA) for Windows.Goffin et al. Arthritis Research & Therapy 2010, 12:R73
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Results
Proteasome inhibition abrogates the production of type I 
collagen induced by TGF-β
We previously reported that PI decreases type I collagen
and TIMP-1 production in human dermal fibroblasts
[21]. Since type I collagen has a trimeric structure com-
posed of two alpha1 subunits and one alpha2 subunit, we
explored whether PI affected the transcription of both the
COL1A1 and COL1A2 genes. Bortezomib decreased both
COL1A1  (10-fold) and COL1A2  (5-fold) steady-state
mRNA levels in a time-dependent manner (Figure 1a, b),
as assessed by quantitative PCR. Bortezomib had only
modest effects on TIMP-1 mRNA levels (Figure 1c). As
expected, TGF-β induced a time-dependent increase in
COL1A1 and COL1A2 mRNA levels (Figure 1a-c). Inter-
estingly, the addition of bortezomib 1 hour before TGF-β
completely abolished the effect of TGF-β on COL1A1 and
COL1A2 (Figure 1a, b). Bortezomib also inhibited, albeit
to a lesser extent, TGF-β-induced TIMP-1 transcription
(Figure 1c). Consistent with these results, bortezomib
strongly inhibited the production of type I collagen and
TIMP-1 proteins induced by TGF-β (Figure 1d, e).
TGF-β activates the transcription of COL1A1 and COL1A2 via 
AP2 and SP1 binding sites, respectively
Transcriptional activation of the COL1A2 gene by TGF-β
is controlled mainly by SP1 binding sites in its promoter
region [9] (Figure 2a), whereas TGF-β activation of the
COL1A1  gene in human dermal fibroblasts remains
poorly understood. To partially characterize the require-
ments for TGF-β responsiveness, we performed
luciferase reporter gene assays in human dermal fibro-
blasts to compare the activity of a full-length COL1A1
promoter with that of a COL1A1 promoter lacking AP2,
SP3/SP1, NF-1, and SP1 binding sites [32] (Figure 2a).
TGF-β stimulated the full-length COL1A1  promoter,
resulting in a threefold increase in the transcriptional
activity after 16 hours of incubation. This increase was
transient and lost by 24 hours of incubation (Figure 2b).
Interestingly, TGF-β had no effect on the activity of the
deleted COL1A1 promoter or the constitutive SV40 pro-
moter used as negative control. These experiments indi-
cate that at least one of the transcription factor binding
sites (AP2, SP3/SP1, NF-1, SP1) present in the promoter
proximal region is required for TGF-β induction of
COL1A1 transcription. To assess whether the observed
increase in COL1A1 promoter activity induced by TGF-β
correlated with an in vivo increase in the binding of spe-
cific transcription factors, we performed chromatin
immunoprecipitation (ChIP) experiments using SP1- and
AP2-specific anti-sera. TGF-β induced a substantial
i n c r e a s e  i n  b i n d i n g  o f  A P 2 ,  b u t  n o t  o f  S P 1 ,  t o  t h e
COL1A1 promoter (Figure 2c). This was distinctly differ-
ent from the observed increase in binding of SP1, but not
of AP2, to the promoter region of COL1A2 in response to
TGF-β (Figure 2c). Thus, the coordinated increase in
COL1A1 and COL1A2 gene transcription in response to
TGF-β is mediated, at least in part, by distinct transcrip-
tion factors.
Proteasome inhibition abolishes TGF-β-induced SP1 
binding to COL1A2 but not of AP2 to COL1A1
We next determined whether PI could affect binding of
the identified transcription factors involved in type I col-
lagen gene activation by TGF-β. We quantified binding of
AP2 and SP1 to the COL1A1  and  COL1A2  promoter
regions in fibroblasts cultured in the presence of TGF-β
or bortezomib or both. As expected, TGF-β increased
binding of AP2 to COL1A1 and SP1 to COL1A2. Con-
versely, bortezomib potently inhibited the binding of AP2
and SP1 to their respective promoter regions in unstimu-
lated fibroblasts (Figure 2d). Of major interest, borte-
zomib abolished TGF-β-induced binding of SP1 to
COL1A2 (0.6- versus 4.8-fold) but failed to significantly
affect TGF-β-induced binding of AP2 to COL1A1 (3.0-
versus 3.5-fold) (Figure 2d). Thus, COL1A1 and COL1A2
promoter regions are bound by different transcription
factors in response to TGF-β and their binding is affected
differently by PI.
Proteasome inhibition does not affect TGF-β-induced 
Smad2 phosphorylation, nuclear translocation, or binding 
to the COL1A2 promoter
TGF-β-mediated activation of the COL1A2 gene is trig-
gered by binding of a transcription factor complex com-
prising SP1, p300, and Smad2/3 to the SP1 sites in its
promoter region [9]. We were interested in investigating
whether the inhibitory effect of PI on SP1 binding to
COL1A1 could be due to its effects on Smad2 signaling.
We therefore studied the fate of Smad2 in fibroblasts cul-
tured in the presence of TGF-β or bortezomib or both. As
expected, TGF-β triggered a pronounced phosphoryla-
tion of Smad2 in dermal fibroblasts. This phosphoryla-
tion was strong at 45 minutes and then decreased,
although it remained detectable after 12 hours (Figure
3a). Bortezomib did not induce Smad2 phosphorylation
on its own and did not modify Smad2 phosphorylation
induced by TGF-β (Figure 3a). Bortezomib was active,
however, since c-Jun phosphorylation was induced as
expected [21] at late time points (Figure 3a).
Upon phosphorylation, Smad2 is known to translocate
into the nucleus in response to TGF-β [34]. Pre-incuba-
tion of fibroblasts with bortezomib did not alter the cyto-
plasmic pattern of Smad2 in resting fibroblasts or its
nearly complete nuclear translocation at 1 hour after the
addition of TGF-β (Figure 3b). Furthermore, bortezomib
did not alter the exclusive nuclear localization of p300,
regardless of the presence or absence of TGF-β (FigureGoffin et al. Arthritis Research & Therapy 2010, 12:R73
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3b). Finally, using a synthetic biotinylated probe
(sequence in Table 1) in a pull-down assay, we quantified
binding of phospho-Smad2 to the SP1 sequence of the
COL1A2 promoter. In these experiments, TGF-β induced
a substantial increase in binding of phospho-Smad2. The
simultaneous presence of bortezomib did not reduce but
instead enhanced binding of phospho-Smad2 in response
to TGF-β, while bortezomib on its own did not induce
any binding (Figure 3c). Taken together, these findings
demonstrate that PI does not alter TGF-β-induced
Smad2 phosphorylation, nuclear translocation, or bind-
ing to the COL1A2 promoter. Impaired Smad2 activation
thus cannot explain the reduced production of collagen
when fibroblasts are stimulated by TGF-β in the presence
of PI.
Differential effects of proteasome inhibition and TGF-β on 
MMP-1 and MMP-2
MMPs play a major role in ECM degradation and are dif-
ferentially regulated by TGF-β, which was reported to
decrease MMP-1 and increase MMP-2 production by
fibroblasts [16,18]. We were therefore interested in inves-
tigating the effect of PI on MMP production in the pres-
ence or absence of TGF-β. We confirmed that
bortezomib stimulated MMP-1 production and that this
increase was dominant over the inhibitory effect of TGF-
Figure 1 Proteasome inhibition reverses the pro-fibrotic effects of TGF-β in dermal fibroblasts. Fibroblasts were cultured in the presence of 
TGF-β (10 ng/mL) or bortezomib (1 μM) or both (TGF-β was added 1 hour after bortezomib) or were left untreated for the indicated amount of time 
(a-c) or for 48 hours (d, e). mRNA levels for COL1A1 (a), COL1A2 (b), and TIMP-1 (c) were assessed by quantitative polymerase chain reaction and nor-
malized to HsEEF1A1 mRNA levels. The increase in treated cells relative to untreated cells is shown in (a-c). The bars represent the mean ± standard 
deviation of two independent experiments; *P < 0.05, **P < 0.005, and ***P < 0.0005 in comparison with untreated cells. Type I collagen present in 
culture supernatants was quantified by immunoblotting (d) and TIMP-1 by enzyme-linked immunosorbent assay (e). Bars represent the increase in 
protein levels in treated cells relative to untreated cells. A representative identification of type I collagen protein by Western blotting is inserted in (d). 
Bort, bortezomib; COL1A, collagen 1A1; TGF-β, transforming growth factor-beta; TIMP-1, tissue inhibitor of matrix metalloproteinase-1; UT, untreated.Goffin et al. Arthritis Research & Therapy 2010, 12:R73
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β, both at the mRNA and protein levels (Figure 4a, c) [21].
Furthermore, bortezomib modestly decreased basal and
TGF-β induced MMP-2 mRNA expression (Figure 4b).
Thus, PI differentially affects the regulation of MMP-1
a n d  M M P - 2  p r o d u c t i o n  i n  f i b r o b l a s t s .  I t  s h o u l d  b e
emphasized that the MMP-1 mRNA half-life in the pres-
ence of the transcriptional inhibitor 5,6-dichlorobenzimi-
dazole riboside (DRB) with and without proteasome
inhibitor exceeded 24 hours (data not shown). However,
steady-state MMP-1 mRNA levels increased in the pres-
ence of PI (Figure 4a). It is thus highly unlikely that MMP-
1 mRNA stability is significantly affected by PI.
Proteasome inhibition activates the MMP-1 promoter by 
inducing binding of c-Jun to the proximal AP-1 site
To identify the promoter sequences that are necessary
and sufficient for driving the induction of MMP-1  in
response to PI, we assessed the impact of bortezomib on
fibroblasts transiently transfected with reporter gene
constructs carrying either an intact MMP-1 promoter or
a mutated MMP-1 promoter in which a binding site for c-
Jun/c-Fos was replaced by a c-Jun/ATF-2 binding site
(Figure 5a and Table 1) [31]. In the presence of borte-
zomib, a 5.1-fold increase in activity of the intact MMP-1
promoter was observed at 4 hours (Figure 5b). This
increase was similar in magnitude to that observed in
cells treated with TNF-α (3.9-fold), which was used as a
positive control. Interestingly, the increase in MMP-1
promoter activity was long-lasting and remained high
after 24 hours of culture (Figure 5b). Mutation of the AP-
1 site in the promoter resulted in a substantial reduction
in MMP-1 induction by bortezomib (2.2-fold at 4 and 24
hours) and unresponsiveness to TNF-α (0.9-fold) (Figure
5b). This demonstrates that optimal bortezomib-induced
activation of MMP-1  transcription requires an AP-1
binding site recognized preferentially by a c-Jun/c-Fos
heterodimer.
Figure 2 Proteasome inhibition abolishes the increased binding of SP1 to COL1A2 but not of AP2 to COL1A1 promoter induced by TGF-β. 
(a) Schematic representation of the COL1A1 and COL1A2 promoter regions and the deleted COL1A1 construct. (b) Dermal fibroblasts were transiently 
transfected with luciferase reporter gene constructs carrying the SV40 promoter, full-length COL1A1 promoter, deleted COL1A1 promoter, or no pro-
moter. Luciferase activity was measured after TGF-β treatment (16 or 24 hours) and normalized to the levels obtained with cells transfected with the 
promoter-free construct. Histograms show the increase in COL1A1 promoter activity in treated cells relative to untreated cells. The results represent 
the mean ± standard deviation (SD) of two independent experiments. (c, d) Fibroblasts were treated with TGF-β (5 ng/mL) for 4 hours or bortezomib 
(1 μM) for 16 hours or both (TGF-β was added 1 hour after bortezomib) for 4 hours or were left untreated. Crosslinked chromatin was extracted, son-
icated, and immunoprecipitated with anti-AP2 or anti-SP1 antibodies. Transcription factor-bound DNA fragments were quantified by real-time poly-
merase chain reaction using the primers indicated in Table 1. The increase in treated cells relative to untreated cells is shown. The bars represent the 
mean ± SD of two independent experiments; *P < 0.05 and ***P < 0.0005 in comparison with untreated cells. Bor, bortezomib; COL1A, collagen 1A; 
ND, not determined; TF, transcription factor; TGF-β, transforming growth factor-beta; UT, untreated.Goffin et al. Arthritis Research & Therapy 2010, 12:R73
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To confirm the involvement of c-Jun in bortezomib-
mediated induction of MMP-1 transcription, we assessed
its in vivo binding to the promoter region of the MMP-1
gene by ChIP. We focused on the promoter proximal
region on the basis of published regulatory sites in the
MMP-1  promoter (Figure 5a) [35] and the results we
obtained using the mutated MMP-1  promoter. Borte-
zomib provoked a strong increase in binding of c-Jun to
the promoter region, comparable to that induced by
TNF-α (3.7- versus 5.2-fold) (Figure 5c). Enhanced bind-
ing of c-Jun to the MMP-1 promoter was specific as the
AP2 transcription factor did not exhibit an increase in
binding upon either treatment, and binding of c-Jun to
the MMP-2 or MMP-9 promoters was not enhanced (Fig-
ure 5c). Thus, the differential effect of bortezomib on
MMP-1 and MMP-2 expression is dependent, at least in
part, on the specific characteristics of their promoter
regions.
The MMP-1 promoter contains at least two proximal
AP-1 binding sites, separated by less than 100 nucle-
otides. Based on the literature, we postulated that the
most proximal site was likely to be the bortezomib-
responsive element. We therefore performed electropho-
retic mobility shift assays (EMSAs) with double-stranded
oligonucleotides corresponding to the most proximal AP-
1 site of the MMP-1 promoter (Table 1 for oligonucle-
otide sequences). Incubation of the MMP-1 probe with
nuclear extracts from untreated fibroblasts (Figure 5d,
left panel) led to the formation of two protein-DNA com-
plexes, of which only the upper band was modulated by
treatment (gray arrow), demonstrating the binding of one
or several transcription factors to this synthetic DNA
sequence. Competition with cold oligonucleotides dem-
Figure 3 Bortezomib does not abrogate TGF-β-induced phosphorylation, nuclear translocation, or binding of Smad2 to the COL1A2 pro-
moter. Fibroblasts were treated with TGF-β (5 ng/mL) or bortezomib (1 μM) or both (TGF-β was added 1 hour after bortezomib) or were left untreated 
for the indicated amount of time. (a) Total protein extracts were analyzed by Western blotting. Band intensities are provided below. (b) Fibroblasts 
were labeled with rabbit anti-p300 or Smad2/3 antibodies. Immunofluorescence photographs (× 40) from one representative experiment out of three 
independent experiments are presented. (c) Nuclear proteins from fibroblasts were extracted and used to perform DNA pull-down assays. DNA-
bound proteins were eluted and analyzed by Western blotting using anti-P-Smad2 antibodies. Total nuclear protein content was assessed using anti-
TFIIEα antibodies on unbound fractions. Band intensities were quantified and normalized to those obtained with the anti-TFIIEα antibody. The increase 
in P-Smad2 levels in treated relative to untreated cells is provided. Bor, bortezomib; B/T, bortezomib/transforming growth factor-beta; COL1A2, colla-
gen 1A2; TGF-β, transforming growth factor-beta; UT, untreated.Goffin et al. Arthritis Research & Therapy 2010, 12:R73
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onstrated the specificity of this binding. The presence of
c-Jun among the bound proteins was indicated by the
appearance of a supershifted band (white arrow) upon
pre-incubation with anti-c-Jun antibodies. No supershift
was observed in the presence of control anti-Ets-1 anti-
bodies (Figure 5d, middle panel). Similar patterns were
obtained with nuclear extracts generated from borte-
zomib- and TNF-α-treated fibroblasts (Figure 5d, right
panel). Finally, DNA pull-down experiments revealed a
marked increase in the amount of c-Jun bound to the
biotinylated MMP-1 probe upon bortezomib treatment
(Figure 5e). Taken together, these experiments demon-
strate that PI results in a specific increase in binding of c-
Jun to the most proximal AP-1 site of the MMP-1 pro-
moter. We next investigated whether binding of c-Jun to
the MMP-1 promoter in the presence of bortezomib was
regulated by TGF-β. This was not the case since ChIP
experiments revealed that bortezomib-induced binding
of c-Jun to the MMP-1  promoter was not affected by
TGF-β (Figure 6a). Of note, under the same culture con-
ditions, TGF-β-induced binding of SP1 to the promoter
region of COL1A2 was abrogated by bortezomib (Figure
6b). In control experiments, binding of c-Jun did not
increase at the COL1A2 promoter, nor did binding of SP1
at the MMP-1 promoter (data not shown). Furthermore,
the specificity of our ChIP assays was emphasized by the
fact that no binding of c-Jun or SP1 was observed within
the open reading frames (ORFs) of the MMP-1  or
COL1A2 genes (Figure 6a, b). In conclusion, the effect of
PI dominates the influence of TGF-β in controlling the
binding of both SP1 to COL1A2 and c-Jun to MMP-1.
Discussion
The major finding of our work is that the overall anti-
fibrotic activity of PI by bortezomib results from two dis-
tinct but functionally converging regulatory effects sum-
marized in Figure 7. On one hand, we have documented
that enhanced transcription of the MMP-1 gene depends
on enhanced binding of c-Jun to the most proximal AP-1
binding site of the MMP-1 promoter. On the other hand,
we have shown that inhibition of SP1 binding to the pro-
moter of COL1A2  correlates with decreased COL1A2
transcription in both unstimulated and TGF-β-stimu-
lated fibroblasts. It is noteworthy that these promoter ele-
ments were previously shown to be important for
regulating the transcription of MMP-1 [35] and COL1A2
[9,36], respectively.
The stimulatory effect we observed on MMP-1 expres-
sion was specific to this particular MMP since borte-
zomib decreased MMP-2 transcription. This could be
explained by the absence of AP-1 binding sites in the
MMP-2 promoter (Figure 5a). However, the MMP-1 pro-
Figure 4 Variations in MMP-1 and MMP-2 expression upon treatment of dermal fibroblasts with bortezomib or TGF-β or both. mRNA and 
protein extracts from treated fibroblasts were processed as described in the legend of Figure 1. The increases in mRNA levels for MMP-1 (a) and MMP-
2 (b) are reported. The data represent the mean ± standard deviation of two independent experiments; *P < 0.05 and ***P < 0.0005 in comparison 
with untreated cells. (c) Protein levels were quantified by immunoblotting for MMP-1. The increase in protein levels in the treated cells relative to un-
treated cells is shown. The analysis of MMP-1 protein by Western blotting is inserted in the upper panel. Data are from a representative experiment. 
Bort, bortezomib; MMP, matrix metalloproteinase; TGF-β, transforming growth factor-beta; UT, untreated.Goffin et al. Arthritis Research & Therapy 2010, 12:R73
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moter shares highly conserved consensus AP-1 binding
sequences with other MMP promoters, including MMP-9
(Figure 5a), which may suggest that the activation by
bortezomib is not restricted to MMP-1. While we have
not directly assessed whether MMP-9 transcription was
enhanced by PI, we did not observe enhanced binding of
c-Jun to the AP-1 site in the promoter of MMP-9. This
may be due to the influence of sequences adjacent to the
AP-1 site or to the composition of the AP-1 complex that
binds there, and this complex could correspond to c-Jun
homodimers or heterodimers of c-Jun with JunB, JunD,
or c-Fos. In particular, a notable difference is the presence
of an Ets-1 site next to the distal AP-1 site (-1604) in
MMP-1 but not in MMP-9. In agreement with previous
observations [37], we postulate that the presence of an
Ets-1 site next to an AP-1 sequence enhances the binding
of c-Jun to the AP-1 site, thereby increasing transcription
of the downstream gene. This is consistent with the find-
ing that bortezomib-induced MMP-1 transcription is
reduced in reporter gene assays when the Ets-1 site in the
MMP-1 promoter is mutated.
Our investigation of the effect of bortezomib on type I
collagen synthesis revealed that reduced COL1A2 tran-
scription correlated with decreased binding of SP1 to the
COL1A2 promoter. This was observed under both basal
and TGF-β-induced conditions. Since we previously
demonstrated that PI did not affect COL1A1 mRNA sta-
bility [21], decreased transcription explains the PI effect.
SP1 is known to be a crucial cis-acting element for basal
COL1A2 transcription and also to play an important role
in mediating TGF-β-induced transcription [8,38]. Fur-
thermore, hyper-phosphorylation of SP1 is characteristic
Figure 5 Bortezomib activates the MMP-1 promoter via binding of c-Jun. (a) Schematic representation of MMP promoter regions. Transcription 
factor (TF) binding sites and TATA boxes are shown (adapted from [35]). (b) Luciferase reporter gene experiments were performed as described in 
Figure 2b, except that the constructs carried the SV40, wild-type, or variant MMP-1 promoter or no promoter. Luciferase activity was measured after 
bortezomib (4 or 24 hours) or TNF-α (1 hour) treatment, normalized, and reported as in Figure 2b. The results represent the mean ± standard deviation 
(SD) of two independent transfections. (c) Fibroblasts were treated for 1 hour with TNF-α (10 ng/mL) or for 16 hours with bortezomib (1 μM). Chro-
matin immunoprecipitation was performed with anti-c-Jun or anti-AP2 antibodies, and the results were quantified by real-time polymerase chain re-
action using the primers indicated in Table 1. The increase in binding of c-Jun or AP2 to the MMP promoters in treated cells relative to untreated cells 
is shown. The results represent the mean ± SD of three independent experiments; *P < 0.05 in comparison with untreated cells. (d, e) Nuclear extracts 
were prepared from fibroblasts that were treated for 16 hours with 1 μM bortezomib or 1 hour with 10 ng/mL TNF-α or that were left untreated. Bind-
ing of TF to a synthetic AP-1 site was assessed by electrophoretic mobility shift assay (d) using a specific radiolabeled probe in the presence (+) or 
absence (-) of anti-Ets or anti-c-Jun antibodies or cold probe (AP-1). A gray arrow indicates band shift, and a white arrow indicates supershifted band. 
Alternatively, TF-DNA binding was assessed by a DNA pull-down assay (e) using a biotinylated MMP-1 probe and anti-c-Jun antibodies. Total nuclear 
protein content was assessed using anti-TFIIEα antibodies on unbound fractions. Bor, bortezomib; MMP, matrix metalloproteinase; ND, not deter-
mined; NE, nuclear extract; TNF-α, tumor necrosis factor-alpha; UT, untreated; WT, wild-type.Goffin et al. Arthritis Research & Therapy 2010, 12:R73
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Figure 6 Bortezomib and TGF-β exert opposing regulation on COL1A and MMP-1 genes. Fibroblasts were treated with TGF-β (5 ng/mL) for 4 
hours or bortezomib (1 μM) for 16 hours or both (TGF-β was added 1 hour after bortezomib) for 4 hours or were left untreated. Chromatin immuno-
precipitations were performed with anti-c-Jun and anti-SP1 antibodies, and the results were quantified by real-time polymerase chain reaction using 
primers hybridizing the promoter (black bar) or the open reading frame (ORF) (white bar) region of either gene (Table 1). The increases in binding of 
c-Jun to the MMP-1 promoter (a) and of SP1 to the COL1A2 promoter (b) in treated cells relative to untreated cells are reported. Specificity of the ex-
periments was controlled by assessing binding of c-Jun or SP1 to the ORF of the MMP-1 (a) and COL1A2 (b) genes, respectively. The data represent the 
mean ± standard deviation of three independent experiments; **P < 0.005 and ***P < 0.0005 in comparison with untreated cells. Bor, bortezomib; B/
T, bortezomib/transforming growth factor-beta; COL1A, collagen 1A; MMP, matrix metalloproteinase; TGF-β, transforming growth factor-beta; UT, un-
treated.Goffin et al. Arthritis Research & Therapy 2010, 12:R73
http://arthritis-research.com/content/12/2/R73
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of SSc dermal fibroblasts [39]. It is therefore likely that
the effect of bortezomib on type I collagen synthesis is
mediated, at least in part, by its capacity to reduce SP1
binding to the promoter of COL1A2. We were unable,
however, to link decreased SP1 binding to upstream
events. In particular, we tested the hypothesis that
reduced SP1 binding might be associated with an effect of
bortezomib on canonical Smad signaling in response to
TGF-β. Indeed, recent studies on TGF-β signaling have
revealed the ability of Smads to interact with various
components of the 26S proteasome system [40]. Such
interactions are now known to contribute to the regula-
tion of Smad protein levels before and after Smad activa-
tion [41]. Most importantly, such interactions have also
been shown to contribute to the signaling functions of
Smads. This involves interactions with several proteins,
such as Smad ubiquitination regulatory factors (Smurfs),
the oncoprotein SnoN, and the multi-domain docking
protein HEF1. Proteasomal degradation of these proteins
links TGF-β signaling to multiple signaling pathways [42].
In our experimental conditions, however, bortezomib did
not affect Smad2 phosphorylation or nuclear transloca-
tion and actually increased its binding to the COL1A2
promoter. In this context, it could be speculated that
increased affinity of a single factor can have a negative
effect on transcription, and this may explain the negative
effect of bortezomib on COL1A2 synthesis. TGF-β-stim-
ulated transcription of COL1A2 is triggered by binding of
a large transcription factor complex, which is composed
of Smad2/3, Smad4, SP1, and the transcription factor
p300 [43]. In this complex, Smad2/3 has been reported to
interact directly with both SP1 and p300 [44]. Although
no direct interaction between SP1 and p300 has been
reported at the COL1A2 promoter, a recent study demon-
strated that SP1 binds p300 and recruits it for NECL1
transcription [45]. Since bortezomib did not prevent
Smad2 binding to COL1A2, it can be hypothesized that it
affects SP1 directly or perturbs in a more subtle manner
the interactions of SP1 with Smad2/3 or p300. In this
respect, it is interesting to note that p300/CBP sequestra-
tion by c-Jun or STAT1 has been proposed to explain, at
least in part, the antagonism exerted on collagen synthe-
sis by TNF-α and interferon-gamma, respectively
[44,46,47]. Thus, c-Jun, which we have demonstrated to
be increased in PI-treated fibroblasts [21], is known to
participate in the functional availability of p300 [48,49].
In addition, PI has been shown to affect the histone
acethyltransferase activity of p300 [50,51], which could
affect binding of transcription factors to the COL1A2
promoter. Finally, off-DNA complexes formed by the
increased availability of c-Jun with other specific or gen-
eral transcription factors may be at play. In the present
work, we have not directly assessed the effect of borte-
zomib on SSc fibroblasts. However, in terms of type I col-
Figure 7 Bortezomib overrides the effect of TGF-β and imposes its anti-fibrotic activity. Schematic representation of the effect of bortezomib 
(left), TGF-β (middle), and bortezomib plus TGF-β (right) on transcription of the MMP-1, COL1A1, and COL1A2 genes. See the Discussion section of the 
text for details. Bor, bortezomib; COL1A, collagen 1A; MMP-1, matrix metalloproteinase-1; TGF-β, transforming growth factor-beta.Goffin et al. Arthritis Research & Therapy 2010, 12:R73
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lagen and MMP-1 protein production, SSc and control
fibroblasts were previously found to behave similarly
when submitted to PI [21].
Conclusions
By altering the binding of at least two transcription fac-
tors, c-Jun and SP1, PI results in increased production of
MMP-1 and decreased synthesis of type I collagen in
human dermal fibroblasts, thus providing a novel ratio-
nale for assessing the potential of drugs targeting the pro-
teasome for their anti-fibrotic properties.
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